Neuro Startup Makes Debut With $20.9M From Novo, Johnson & Johnson Post author:Sam Post published:February 8, 2018 Post category:BioPharma Syndesi will work to modulate the synaptic vesicle protein SV2A. Source: BioSpace You Might Also Like Daiichi Sankyo Terminates $650 Million Deal With This U.S. Pharma August 30, 2017 AstraZeneca PLC Eases Its Migraine With $302 Million Sale June 6, 2017 Oxford Immunotec Schedules First Quarter 2017 Earnings Release And Conference Call For May 2, 2017 April 19, 2017
Oxford Immunotec Schedules First Quarter 2017 Earnings Release And Conference Call For May 2, 2017 April 19, 2017
